Quote | SAB Biotherapeutics Inc. (NASDAQ:SABS)
Last: | $2.85 |
---|---|
Change Percent: | -3.11% |
Open: | $3.0109 |
Close: | $2.85 |
High: | $3.0145 |
Low: | $2.85 |
Volume: | 2,255 |
Last Trade Date Time: | 07/18/2024 03:00:00 am |
News | SAB Biotherapeutics Inc. (NASDAQ:SABS)
SAB Biotherapeutics, Inc. (NASDAQ: SABS) is one of today's top gainers. The company's shares have moved 0% on the day to $2.77. SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advance...
2024-06-20 09:24:26 ET More on SAB Biotherapeutics: Seeking Alpha’s Quant Rating on SAB Biotherapeutics Historical earnings data for SAB Biotherapeutics Financial information for SAB Biotherapeutics Read the full article on Seeking Alpha For fu...
Message Board Posts | SAB Biotherapeutics Inc. (NASDAQ:SABS)
Subject | By | Source | When |
---|---|---|---|
$SABS bears are running | XenaLives | investorshub | 05/14/2023 11:30:21 PM |
$SABS should we be shorting? | crudeoil24 | investorshub | 05/13/2023 2:03:54 AM |
Price gaining | XenaLives | investorshub | 05/11/2023 12:26:26 AM |
The gaining | XenaLives | investorshub | 05/09/2023 12:34:18 PM |
$SABS The now | XenaLives | investorshub | 05/06/2023 2:17:08 PM |
News, Short Squeeze, Breakout and More Instantly...
SAB Biotherapeutics Inc. Company Name:
SABS Stock Symbol:
NASDAQ Market:
SAB Biotherapeutics Inc. Website:
SAB Biotherapeutics, Inc. (NASDAQ: SABS) is one of today's top gainers. The company's shares have moved 0% on the day to $2.77. SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advance...
New name, logo and website updates, stock symbol will remain SABS With new brand identity, SAB BIO continues drive towards serious unmet needs in type 1 diabetes MIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB...
MIAMI, June 18, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progre...